Entera Bio Q2 2024 net loss $2.1M; cash runway into Q3 2025; EB613 milestone expected

Entera Bio Ltd.

2024-Q2 EPS reported $0.11 revenue$57,000

Net loss of $2.1M ($0.06 per share) vs $2.3M ($0.08) in Q2 2023; cash $9.1M at June 30, 2024.
R&D expenses $1.1M (down $0.1M YoY); G&A flat at $1.1M; operating expenses $2.2M.
EB613 (oral PTH) Phase 2 data published in JBMR; FDA SABRE endpoint ruling expected ~5 months.
EB612 hypoparathyroidism Phase 1 data at ENDO 2024; potential move to Phase 2 soon.
Collaboration with OPKO on oral GLP-2 (short bowel) and GLP-1/glucagon (obesity) ongoing; PK data due H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.